

Pamela Maffioli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4447585/pamela-maffioli-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182 papers	4,509 citations	37 h-index	57 g-index
195 ext. papers	5,340 ext. citations	4.7 avg, IF	5.98 L-index

#	Paper	IF	Citations
182	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, L. and , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 847240	5.7	0
181	Quercetin Phytosome□ as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , 2021 , 67, 190-195	3	11
180	Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. <i>Frontiers in Medicine</i> , 2021 , 8, 605691	4.9	5
179	Quercetin Phytosome□ as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , 2021 , 67,	3	5
178	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , 2021 , 12, 582556	8.4	2
177	Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. <i>International Journal of General Medicine</i> , 2021 , 14, 2359-2366	2.3	38
176	Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. <i>International Journal of General Medicine</i> , 2021 , 14, 2807-2816	2.3	44
175	Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimicina), White Mulberry and Chromium Picolinate in Nondiabetic Subects with Dysglycemia: A Randomized Trial. <i>Life</i> , 2021 , 11,	3	1
174	Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function. <i>Archives of Medical Science</i> , 2021 , 17, 1087-1092	2.9	0
173	A role for quercetin in coronavirus disease 2019 (COVID-19). <i>Phytotherapy Research</i> , 2021 , 35, 1230-1236	6.7	78
172	Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 5367-5374	4.4	4
171	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 653-661	3.4	9
170	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 845-859	1.9	7
169	Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. <i>International Journal for Vitamin and Nutrition Research</i> , 2020 , 1-10	1.7	2
168	Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. <i>Nutrition</i> , 2020 , 73, 110700	4.8	12
167	Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markERs in the progreSsion of diabeteS in obese paTleNTs (The RESISTIN trial). <i>Cytokine</i> , 2020 , 127, 154947	4	22
166	Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3219	7.5	3

165	Ilex paraguariensis, white mulberry and chromium picolinate in patients with pre-diabetes. <i>Phytotherapy Research</i> , 2020 , 34, 1377-1384	6.7	2
164	Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 1391-1399	2.9	5
163	Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglycemic patients. <i>Phytotherapy Research</i> , 2019 , 33, 791-797	6.7	9
162	Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 3647-3655	4.4	9
161	Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019 , 12, 1861-1865	3.4	5
160	Effects of a nutraceutical combination of monacolin, Ebryanol and ̢aminobutyric acid on lipid profile and C-reactive protein in mice. <i>Archives of Medical Science</i> , 2019 , 15, 792-796	2.9	1
159	Nutraceutical Herbs and Insulin Resistance 2019 , 223-242		
158	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease. <i>Nutrients</i> , 2019 , 11,	6.7	2
157	Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstlve hearT failure: The COFFEE-IT study. <i>Pharmacological Research</i> , 2019 , 141, 46-52	10.2	2
156	Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. <i>Phytomedicine</i> , 2018 , 42, 75-82	6.5	12
155	The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. <i>Journal of Cellular Physiology</i> , 2018 , 233, 153-161	7	96
154	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. <i>Journal of Cellular Physiology</i> , 2018 , 233, 1791-1795	7	3
153	Curcumin: A Natural Pan-HDAC Inhibitor in Cancer. <i>Current Pharmaceutical Design</i> , 2018 , 24, 123-129	3.3	34
152	Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption. <i>Archives of Medical Science</i> , 2018 , 14, 760-765	2.9	1
151	Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 1637-1640	2.9	7
150	Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33]. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 122, 504	5.1	
149	A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 2611-2616	4.4	4
148	Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. <i>Cytokine</i> , 2017 , 92, 75-79	4	6

147	Exosomes: Nanoparticulate tools for RNA interference and drug delivery. <i>Journal of Cellular Physiology</i> , 2017 , 232, 1660-1668	7	62
146	Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1380-1396	3.8	11
145	Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1248	3.2	
144	Retraction notice to "Evaluation of the positive effects on insulin-resistance and β -cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients" [Pharmacol. Res. 73 (2013) 20-26]. <i>Pharmacological Research</i> , 2017 , 121, 255	10.2	1
143	Naturally occurring anti-cancer agents targeting EZH2. <i>Cancer Letters</i> , 2017 , 400, 325-335	9.9	44
142	Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q on lipid levels: a randomized, double-blind, placebo controlled study. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1585-1592	4.4	17
141	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 3425-3434	4.4	8
140	Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 2293-2300	4.4	4
139	Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis. <i>Phytotherapy Research</i> , 2017 , 31, 1836-1841	6.7	15
138	Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. <i>Cardiovascular Therapeutics</i> , 2017 , 35, 47-54	3.3	5
137	Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1481-1488	4.4	23
136	Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	12
135	Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	4
134	Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adiponectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Current Pharmaceutical Design</i> , 2017 , 23, 870-878	3.3	7
133	The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. <i>Clinical Nutrition</i> , 2016 , 35, 1091-5	5.9	19
132	Auraptene and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 929, 399-407	3.6	14
131	Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies: A Randomized, Controlled, Clinical Trial. <i>Medicine (United States)</i> , 2016 , 95, e3084	1.8	6
130	Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 66	2.3	13

129	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , 2016 , 76, 947-56	12.1	38
128	Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 335-45	4.5	141
127	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016 , 212, 160-8	3.2	39
126	Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. <i>Autoimmunity Reviews</i> , 2016 , 15, 344-53	13.6	37
125	A Clinical Trial about a Food Supplement Containing Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	39
124	A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus. <i>Vascular Health and Risk Management</i> , 2016 , 12, 415-419	4.4	17
123	Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016 , 111, 394-404	10.2	102
122	A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa (black seed) on blood pressure. <i>Journal of Hypertension</i> , 2016 , 34, 2127-35	1.9	26
121	Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 819-34	3.8	20
120	Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles 2016 , 3-26		
119	Ellagic Acid and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 928, 473-479	3.6	47
118	Piperine and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 928, 173-184	3.6	37
117	Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 807-18	3.8	27
116	Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. <i>BioFactors</i> , 2016 , 42, 316-22	6.1	32
115	Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. <i>Pharmacological Research</i> , 2015 , 100, 127-34	10.2	13
114	Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. <i>Expert Review of Endocrinology and Metabolism</i> , 2015 , 10, 297-304	4.1	7
113	Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , 2015 , 102, 63-70	10.2	54
112	Inhaled insulin: weighing the pros and cons. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 834-5	18.1	1

111	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. <i>European Journal of Pharmacology</i> , 2015 , 766, 31-6	5.3	9
110	EXAMINE: targeting risk and treatment in diabetes. <i>Lancet, The</i> , 2015 , 386, 1443	4.0	2
109	Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 409-14	2.9	4
108	Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 822		
107	Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": J Am Soc Hypertens 8 (2014) 422-428. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 822		
106	Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. <i>Hypertension Research</i> , 2015 , 38, 690-4	4.7	12
105	Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. <i>Scientific Reports</i> , 2015 , 5, 12603	4.9	3
104	Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 1136-41	3.2	1
103	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2015 , 14, 95	8.7	7
102	Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial. <i>Pharmacotherapy</i> , 2015 , 35, 983-90	5.8	5
101	Sulfonylureas and their use in clinical practice. <i>Archives of Medical Science</i> , 2015 , 11, 840-8	2.9	220
100	6D.07. <i>Journal of Hypertension</i> , 2015 , 33, e84	1.9	
99	Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. <i>Atherosclerosis</i> , 2015 , 239, 87-92	3.1	24
98	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015 , 108, 329-35	7.4	23
97	Berberis aristata/Silybum marianum fixed combination (Berberol(®)) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. <i>Phytomedicine</i> , 2015 , 22, 231-7	6.5	18
96	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. <i>Annals of Medicine</i> , 2015 , 47, 47-52	1.5	7
95	Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles 2015 , 1-24		1
94	Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. <i>Inflammation</i> , 2014 , 37, 154-62	5.1	5

93 Pharmacotherapy for Obesity **2014**, 261-277

92	Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. <i>European Journal of Pharmaceutical Sciences</i> , 2014 , 51, 26-33	5.1	7
91	Diabetes: safety and efficacy of albiglutide-results from two trials. <i>Nature Reviews Endocrinology</i> , 2014 , 10, 514-6	15.2	
90	Glibenclamide and cardio-metabolic risk: a systematic review. <i>International Journal of Diabetes in Developing Countries</i> , 2014 , 34, 61-68	0.8	1
89	Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 422-8		5
88	Dietary and nutraceutical approach to type 2 diabetes. <i>Archives of Medical Science</i> , 2014 , 10, 336-44	2.9	41
87	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 957-67	12.7	23
86	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. <i>Fundamental and Clinical Pharmacology</i> , 2014 , 28, 221-9	3.1	23
85	Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. <i>Current Topics in Medicinal Chemistry</i> , 2014 , 14, 200-6	3	38
84	Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. <i>Pharmacotherapy</i> , 2013 , 33, 817-26	5.8	19
83	Adipocytokine levels in obese and non-obese subjects: an observational study. <i>Inflammation</i> , 2013 , 36, 914-20	5.1	71
82	Effects of canrenone in patients with metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 2161-9	4	12
81	Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1495-506	5.4	37
80	Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. <i>Clinical and Experimental Hypertension</i> , 2013 , 35, 301-7	2.2	5
79	Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. <i>Journal of the American Society of Hypertension</i> , 2013 , 7, 32-9		7
78	Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. <i>Nutrition Research</i> , 2013 , 33, 622-8	4	49
77	Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 719-28	2.5	4
76	A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15, 214-22	8.1	14

75	Effects of berberine on lipid profile in subjects with low cardiovascular risk. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 475-82	5.4	64
74	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 1113-22	2.2	12
73	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 621-9	4.1	4
72	Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 371-84	4	4
71	Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013 , 91, 724-32	2.4	14
70	Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. <i>Internal Medicine</i> , 2013 , 52, 2179-87	1.1	23
69	A curious case of hypoglycaemia. <i>Archives of Medical Science</i> , 2013 , 9, 752-4	2.9	1
68	Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. <i>Archives of Medical Science</i> , 2013 , 9, 238-42	2.9	6
67	Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012 , 37, 187-95	2.2	35
66	Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 341-7	6.7	11
65	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , 2012 , 59, 611-9	2.9	9
64	Vildagliptin added to metformin on β cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 475-84	8.1	41
63	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β cell function. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2433-42	4	18
62	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 553-64	4.9	43
61	Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1113-24	5.4	123
60	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β cell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012 , 98, 51-60	7.4	54
59	Exenatide plus metformin compared with metformin alone on β cell function in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2012 , 29, 1515-23	3.5	48
58	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1091-9	4	9

57	Glucosidase inhibitors and their use in clinical practice. <i>Archives of Medical Science</i> , 2012 , 8, 899-906	2.9	194
56	Optimizing glycemic control: clinical utility of exenatide prolonged release injection. <i>Research and Reports in Endocrine Disorders</i> , 2012 , 41		
55	Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. <i>Clinical Cardiology</i> , 2012 , 35, 359-64	3.3	23
54	Anti-obesity drugs: a review about their effects and their safety. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 459-71	4.1	129
53	Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. <i>Clinical Therapeutics</i> , 2012 , 34, 1221-36	3.5	47
52	GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. <i>Current Clinical Pharmacology</i> , 2012 , 7, 214-28	2.5	39
51	Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. <i>Current Medical Research and Opinion</i> , 2012 , 28, 1435-45	2.5	18
50	Dipeptidyl peptidase-4 inhibitors: 3 years of experience. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 350-64	8.1	45
49	Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 629-36	4	8
48	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2581-91	4	21
47	Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 164-71	2.2	33
46	Peroxisome proliferator-activated receptor- γ (PPAR- γ) agonists on glycemic control, lipid profile and cardiovascular risk. <i>Current Molecular Pharmacology</i> , 2012 , 5, 272-81	3.7	51
45	Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. <i>Hypertension Research</i> , 2011 , 34, 1321-6	4.7	21
44	Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2011 , 91, 265-70	7.4	19
43	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2011 , 4, 263-71	3.4	21
42	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011 , 36, 592-601	2.2	8
41	Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , 2011 , 25, 642-51	3.1	22
40	Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2011 , 60, 421-9	12.7	28

39	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , 2011 , 651, 240-50	5.3	41
38	Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. <i>European Journal of Pharmacology</i> , 2011 , 666, 251-6	5.3	57
37	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , 2011 , 113, 950-960	3	16
36	Drug safety evaluation of amlodipine. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 795-804	4.1	17
35	Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2441-8	4	12
34	Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. <i>Hormone and Metabolic Research</i> , 2011 , 43, 505-12	3.1	27
33	Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1351-8	4	12
32	Nifedipine and telmisartan for the treatment of hypertension: the TALENT study. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 1499-503	2.5	2
31	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , 2011 , 34, 145-51	4.7	31
30	Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010 , 35, 565-79	2.2	29
29	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2010 , 13, 378-90	3.4	10
28	Candesartan effect on inflammation in hypertension. <i>Hypertension Research</i> , 2010 , 33, 209-13	4.7	18
27	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1971-82	4	25
26	Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 835-43	2.5	12
25	Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. <i>Hormone and Metabolic Research</i> , 2010 , 42, 663-9	3.1	45
24	Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. <i>Hormone and Metabolic Research</i> , 2010 , 42, 8-13	3.1	36
23	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , 2010 , 33, 790-5	4.7	21
22	Effects of thiazolidinediones and sulfonylureas in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , 2010 , 12, 491-501	8.1	28

21	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , 2010 , 79, 144-9	3.7	22
20	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , 2010 , 80, 110-5	3.7	24
19	Exenatide versus glibenclamide in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , 2010 , 12, 233-40	8.1	97
18	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , 2010 , 57, 777-86	2.9	42
17	Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. <i>Internal Medicine</i> , 2010 , 49, 1717-25	1.1	29
16	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2010 , 59, 887-95	12.7	93
15	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1973-83	2.5	33
14	Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11, 159-69	8.1	16
13	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , 2009 , 24, 204-10	2.1	37
12	Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11, 1091-9	6.7	36
11	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , 2009 , 63, 723-33	7.5	14
10	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60@ study. <i>Metabolism: Clinical and Experimental</i> , 2009 , 58, 1059-66	12.7	18
9	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. <i>Current Medical Research and Opinion</i> , 2009 , 25, 607-15	2.5	30
8	Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1239-47	4	22
7	Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. <i>Internal Medicine</i> , 2009 , 48, 265-71	1.1	10
6	Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). <i>Endocrine Journal</i> , 2009 , 56, 571-8	2.9	5
5	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , 2009 , 32, E124-32	0.9	32
4	Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. <i>Archives of Medical Research</i> , 2008 , 39, 412-9	6.6	15

- 3 Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. *Metabolism: Clinical and Experimental*, **2008**, 57, 1552-7 12.7 14
- 2 Matrix metalloproteinase-2 and -9 levels in obese patients. *Endothelium: Journal of Endothelial Cell Research*, **2008**, 15, 219-24 107
- 1 Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease. *European Medical Journal Diabetes*, 70-78 1